Patents by Inventor Christopher Andrew Luckhurst

Christopher Andrew Luckhurst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYR ROLE-5(1H)-CARBONITRILE AS USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS
    Publication number: 20230312580
    Abstract: The present invention relates to hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitriles with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis:.
    Type: Application
    Filed: June 7, 2021
    Publication date: October 5, 2023
    Inventors: Christopher Andrew LUCKHURST, Mark Ian KEMP, Paul William THOMPSON, Martin Lee STOCKLEY
  • N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS
    Publication number: 20230303547
    Abstract: The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquity lating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: (formulae (I)(i) and (I)(ii)).
    Type: Application
    Filed: June 3, 2021
    Publication date: September 28, 2023
    Inventors: Christopher Andrew LUCKHURST, Mark Ian KEMP, Paul William THOMPSON
  • N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION
    Publication number: 20230219939
    Abstract: The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: Formula (I), Formula (II).
    Type: Application
    Filed: May 27, 2021
    Publication date: July 13, 2023
    Inventors: Christopher Andrew LUCKHURST, Mark Ian KEMP, Paul William THOMPSON
  • N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS
    Publication number: 20230119013
    Abstract: The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis.
    Type: Application
    Filed: April 7, 2021
    Publication date: April 20, 2023
    Inventors: Christopher Andrew LUCKHURST, Mark Ian KEMP, Paul William THOMPSON
  • SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS
    Publication number: 20220315572
    Abstract: The present invention relates to a class of substituted-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: (I).
    Type: Application
    Filed: September 3, 2020
    Publication date: October 6, 2022
    Inventors: Paul William THOMPSON, Christopher Andrew LUCKHURST, Mark Ian KEMP
  • Novel Compounds 010
    Publication number: 20110201581
    Abstract: The present invention provides compounds of formula (I) in which n, y, X1, X2, A, B, R1, R2, R3, R4 and R5 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: February 11, 2011
    Publication date: August 18, 2011
    Inventors: Mark Furber, Christopher Andrew Luckhurst, Hitesh Jayantilal Sanganee, Linda Anne Stein, Peter Alan Cage
  • Compounds 010
    Patent number: 7902181
    Abstract: The present invention provides compounds of formula (I) in which n, y, X1, X2, A, B, R1, R2, R3, R4 and R5 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: December 10, 2008
    Date of Patent: March 8, 2011
    Assignee: AstraZeneca AB
    Inventors: Mark Furber, Christopher Andrew Luckhurst, Hitesh Jayantilal Sanganee, Linda Anne Stein, Peter Alan Cage
  • Novel Compounds 010
    Publication number: 20090306042
    Abstract: The present invention provides compounds of formula (I) in which n, y, X1, X2, A, B, R1, R2, R3, R4 and R5 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: December 10, 2008
    Publication date: December 10, 2009
    Inventors: Mark Furber, Christopher Andrew Luckhurst, Hitesh Jayantilal Sanganee, Linda Anne Stein, Peter Alan Cage